{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:25:19Z","timestamp":1780514719604,"version":"3.54.1"},"reference-count":24,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reports"],"abstract":"<jats:p>Background and Clinical Significance: In multiple sclerosis (MS), there are many therapeutic options, but most of the available drugs can cause drug-induced liver injury (DILI) after the first infusions. A wide group of other drugs may induce liver injury, from simple anti-pyretic medication like Acetaminophen to various dietary herb supplements like Ashwagandha. Case Presentation: A 39-year-old female patient, diagnosed with MS, has been previously treated with Glatiramer Acetate and interferon-beta, and is currently undergoing immunomodulatory treatment with natalizumab (infusion no. 81). She had a recent history of an airway infection for which she took 4\u20135 capsules of Acetaminophen per day for 7 days, along with the consumption of dietary supplement with Ashwagandha herb. She presented with jaundice, pruritus, and lower limb ecchymoses. The laboratory results revealed higher aminotransferase levels, total bilirubin, and alkaline phosphatase. The screening for autoimmune and infectious hepatitis was negative. The scenario of toxic hepatitis induced by recently used drugs (Ashwagandha dietary herb supplement and Acetaminophen) was adequate to start therapy with oral cortisone. The clinical and laboratory results gradually improved, with normal levels of liver enzymes and bilirubin, with no further increase after the discontinuation of corticosteroid therapy and dietary herb supplements. Conclusions: This case highlights the challenges in determining the multiple etiologies and managing acute liver injury in an MS patient on natalizumab, an immunomodulatory drug that can induce liver injury after the first infusions, especially in the context of recent ingestion of hepatotoxic drugs.<\/jats:p>","DOI":"10.3390\/reports8020038","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T04:17:14Z","timestamp":1742962634000},"page":"38","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Etiopathogenic and Therapeutic Considerations in a Multiple Sclerosis Case with Acute Toxic Hepatitis"],"prefix":"10.3390","volume":"8","author":[{"given":"Maria-Melania","family":"Dumitru-Martoiu","sequence":"first","affiliation":[{"name":"Department of Neurology, Elias Emergency and University Hospital, 011461 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Petrescu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Elias Emergency and University Hospital, 011461 Bucharest, Romania"},{"name":"Department of Clinical Neuroscience, General Medicine, University of Medicine and Farmacy \u201cCarol Davila\u201d, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Aura","family":"Panea","sequence":"additional","affiliation":[{"name":"Department of Neurology, Elias Emergency and University Hospital, 011461 Bucharest, Romania"},{"name":"Department of Clinical Neuroscience, General Medicine, University of Medicine and Farmacy \u201cCarol Davila\u201d, 050474 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Dijm\u0103rescu, I., Gu\u021b\u0103, O.M., Brezeanu, L.E., Dijm\u0103rescu, A.D., Becheanu, C.A., and P\u0103curar, D. (2022). Drug-Induced Hepatitis in Children: The Experience of a Single Center in Romania. Children, 9.","DOI":"10.3390\/children9081136"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL Clinical Practice Guidelines: Drug-induced liver injury","volume":"70","author":"Andrade","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"17562848231163410","DOI":"10.1177\/17562848231163410","article-title":"Drug-induced liver injury: A comprehensive review","volume":"16","author":"Hosack","year":"2023","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_4","unstructured":"(2024, August 03). Clinical Manifestations and Diagnosis of Acetaminophen (Paracetamol) Poisoning in Children and Adolescents\u2014UpToDate. Available online: https:\/\/www.uptodate.com\/contents\/clinical-manifestations-and-diagnosis-of-acetaminophen-paracetamol-poisoning-in-children-and-adolescents."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.redox.2018.04.019","article-title":"Mechanisms of acetaminophen-induced liver injury and its implications for therapeutic interventions","volume":"17","author":"Yan","year":"2018","journal-title":"Redox Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1053\/j.gastro.2019.02.002","article-title":"Incidence and Etiology of Drug-Induced Liver Injury in Mainland China","volume":"156","author":"Shen","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s12664-017-0815-8","article-title":"Clinical outcomes, histopathological patterns, and chemical analysis of Ayurveda and herbal medicine associated with severe liver injury-A single-center experience from southern India","volume":"37","author":"Philips","year":"2018","journal-title":"Indian. J. Gastroenterol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Paul, S., Chakraborty, S., Anand, U., Dey, S., Nandy, S., Ghorai, M., Saha, S.C., Patil, M.T., Kandimalla, R., and Pro\u0107k\u00f3w, J. (2021). Withania somnifera (L.) Dunal (Ashwagandha): A comprehensive review on ethnopharmacology, pharmacotherapeutics, biomedicinal and toxicological aspects. Biomed. Pharmacother., 143.","DOI":"10.1016\/j.biopha.2021.112175"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s40263-021-00842-9","article-title":"The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review","volume":"35","author":"Biolato","year":"2021","journal-title":"CNS Drugs"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(16)32388-1","article-title":"Evolving concepts in the treatment of relapsing multiple sclerosis","volume":"389","author":"Comi","year":"2017","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1007\/s00415-022-11193-w","article-title":"Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: An expert opinion","volume":"269","author":"Filippi","year":"2022","journal-title":"J. Neurol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1177\/1352458512463485","article-title":"Natalizumab-induced autoimmune hepatitis in a patient with multiple sclerosis","volume":"19","author":"Lacruz","year":"2013","journal-title":"Mult. Scler."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1474-4422(18)30069-3","article-title":"Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): A phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension","volume":"17","author":"Kapoor","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e0270","DOI":"10.1097\/HC9.0000000000000270","article-title":"Ashwagandha-induced liver injury-A case series from India and literature review","volume":"7","author":"Philips","year":"2023","journal-title":"Hepatol. Commun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.crtox.2021.02.002","article-title":"DNA damage by Withanone as a potential cause of liver toxicity observed for herbal products of Withania somnifera (Ashwagandha)","volume":"2","author":"Siddiqui","year":"2021","journal-title":"Curr. Res. Toxicol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Lubarska, M., Ha\u0142asi\u0144ski, P., Hryhorowicz, S., Mahadea, D.S., \u0141ykowska-Szuber, L., Eder, P., Dobrowolska, A., and Krela-Ka\u017amierczak, I. (2023). Liver Dangers of Herbal Products: A Case Report of Ashwagandha-Induced Liver Injury. Int. J. Environ. Res. Public Health, 20.","DOI":"10.3390\/ijerph20053921"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/liv.14393","article-title":"Liver Injury due to Ashwagandha. A Case Series from Iceland and the U.S. Drug-Induced Liver Injury Network","volume":"40","author":"Avula","year":"2020","journal-title":"Liver Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.14309\/ajg.0000000000001369","article-title":"Ashwagandha-Induced Liver Injury: Self-Reports on Commercial Websites as Useful Adjunct Tools for Causality Assessment","volume":"116","author":"Weber","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4997\/jrcpe.2021.409","article-title":"Drug-induced hepatocellular injury due to herbal supplement ashwagandha","volume":"51","author":"Ireland","year":"2021","journal-title":"J. R. Coll. Physicians Edinb."},{"key":"ref_22","unstructured":"Rattu, M., Maddock, E., Espinosa, J., Lucerna, A., and Bhatnagar, N. (2022). An Herbal Liver Effect: Ashwagandha-Induced Hepatotoxicity, Department of Emergency Medicine. Available online: https:\/\/rdw.rowan.edu\/cgi\/viewcontent.cgi?article=1194&context=stratford_research_day."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e1931","DOI":"10.14309\/01.ajg.0000868544.04043.fe","article-title":"S2976 Cry Me a Liver: Ashwagandha-Induced Liver Toxicity","volume":"117","author":"Ali","year":"2022","journal-title":"Am. J. Gastroenterol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e7078","DOI":"10.1002\/ccr3.7078","article-title":"Ashwagandha-induced acute liver injury: A case report","volume":"11","author":"Benedek","year":"2023","journal-title":"Clin. Case Rep."}],"container-title":["Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2571-841X\/8\/2\/38\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:00:14Z","timestamp":1760029214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2571-841X\/8\/2\/38"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["reports8020038"],"URL":"https:\/\/doi.org\/10.3390\/reports8020038","relation":{},"ISSN":["2571-841X"],"issn-type":[{"value":"2571-841X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]}}}